Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) for Depression

Phase-Based Progress Estimates
University of Rochester Medical Center, Rochester, NY
Depression+9 More
Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) - Behavioral
All Sexes
What conditions do you have?

Study Summary

The current study aims to assess the acceptability and feasibility of an adapted version of Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) for use with signing Deaf adults. This is a Stage 1A intervention refinement study consisting of a single-arm open pilot trial. Thirty Deaf adults with clinically significant symptoms of alcohol use disorder (AUD), post-traumatic stress disorder (PTSD), depression, anxiety, and/or insomnia, who are not currently engaged in treatment will be recruited from across the United States. All subjects will complete a baseline assessment of their behavioral health symptoms, perceptions towards treatment, and intent to seek treatment prior to engaging in the adapted CBT-TS intervention. The primary clinical outcome, assessed at one-month follow-up, will be whether subjects scheduled professional treatment. Secondary outcomes include changes in subjects' perceptions towards treatment, intentions to seek treatment, and symptom severity from baseline. During the one-month, follow-up assessment subjects will also complete a client satisfaction survey and open-ended questions to provide feedback about the CBT-TS intervention.

Eligible Conditions

  • Depression
  • Alcohol Use Disorder
  • Post Traumatic Stress Disorder (PTSD)
  • Anxiety
  • Mental Health Issue
  • Insomnia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 5 Secondary · Reporting Duration: 1 month

1 month
mean satisfaction with the intervention
proportion of participants who complete the follow up assessments
proportion of participants who schedule professional treatment
proportion of eligible participant who enroll
proportion of participants eligible for the study
proportion of participants who complete the intervention
baseline to 1 month
mean change in attitudes about treatment
mean change in intention to seek treatment
mean change in perceived behavioral control about seeking treatment
mean change in subjective norm about treatment

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

All Participants
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) · No Placebo Group · N/A

All Participants
Experimental Group · 1 Intervention: Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 month
Closest Location: University of Rochester Medical Center · Rochester, NY
Photo of Rochester 1Photo of Rochester 2Photo of Rochester 3
2018First Recorded Clinical Trial
8 TrialsResearching Depression
408 CompletedClinical Trials

Who is running the clinical trial?

University of RochesterLead Sponsor
778 Previous Clinical Trials
489,549 Total Patients Enrolled
24 Trials studying Depression
8,122 Patients Enrolled for Depression

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no current behavioral health treatment.
The primary method of communication is ASL or PSE.
You have a positive screen for one or more behavioral health disorders.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.